---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-022219"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T17:17:33.887098+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated

## Summary
- Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.
- R&D expenses Q4 $32.0M (up 31% YoY), FY2024 $114.1M (up 34%).
- G&A expenses Q4 $7.6M (up 10%), FY2024 $28.8M (up 13%).
- Expects seven data readouts for ORIC-114, ORIC-944 over 18 months; potential registrational trials in 2H25/early 2026.
- Entered J&J collaboration for ORIC-114 + amivantamab in NSCLC; completed $125M private placement.

## SEC filing metadata
- accession: 0000950170-25-022219
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017025022219/0000950170-25-022219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017025022219/oric-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-022219
- JSON: https://secwatch.observer/filing/0000950170-25-022219.json
- Plain text: https://secwatch.observer/filing/0000950170-25-022219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.